[en] BACKGROUND: Patients suffering from combined obstructive and interstitial lung disease (O-ILD) represent a pathological entity which still has to be well clinically described. The aim of this descriptive and explorative study was to describe the phenotype and functional characteristics of a cohort of patients suffering from functional obstruction in a population of ILD patients in order to raise the need of dedicated prospective observational studies and the evaluation of the impact of anti-fibrotic therapies.
METHODS: The current authors conducted a retrospective study including 557 ILD patients, with either obstructive (O-ILD, n = 82) or non-obstructive (non O-ILD, n = 475) pattern. Patients included were mainly males (54%) with a mean age of 62 years.
RESULTS: Patients with O-ILD exhibited a characteristic functional profile with reduced percent predicted forced expired volume in 1 s (FEV1) [65% (53-77) vs 83% (71-96), p < 0.00001], small airway involvement assessed by maximum expiratory flow (MEF) 25/75 [29% (20-41) vs 81% (64-108), p < 0.00001], reduced sGaw [60% (42-75) vs 87% (59-119), p < 0.01] and sub-normal functional residual capacity (FRC) [113% (93-134) vs 92% (75-109), p < 0.00001] with no impaired of carbon monoxide diffusing capacity of the lung (DLCO) compared to those without obstruction. Total lung capacity (TLC) was increased in O-ILD patients [93% (82-107) vs 79% (69-91), p < 0.00001]. Of interest, DLCO sharply dropped in O-ILD patients over a 5-year follow-up. We did not identify a significant increase in mortality in patients with O-ILD. Interestingly, the global mortality was increased in the specific sub-group of patients with O-ILD and no progressive fibrosing ILD phenotype and in those with connective tissue disease associated ILD especially in case of rheumatoid arthritis.
CONCLUSIONS: The authors individualized a specific functional-based pattern of ILD patients with obstructive lung disease, who are at risk of increased mortality and rapid DLCO decline over time. As classically those patients are excluded from clinical trials, a dedicated prospective study would be of interest in order to define more precisely treatment response of those patients.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
GUIOT, Julien ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
HENKET, Monique ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Frix, Anne-Noëlle ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
GESTER, Fanny ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
THYS, Marie ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
GILTAY, Laurie ; Centre Hospitalier Universitaire de Liège - CHU > > Unité équipe mobile Sart Tilman
DESIR, Colin ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiodiagnostic
MOERMANS, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
NJOCK, Makon-Sébastien ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie
MEUNIER, Paul ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de radiodiagnostic
CORHAY, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
LOUIS, Renaud ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie
Language :
English
Title :
Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ?
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Raghu G, Richeldi L. Current approaches to the management of idiopathic pulmonary fibrosis. Respir Med. 2017;129:24–30. DOI: 10.1016/j.rmed.2017.05.017
Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–48. DOI: 10.1164/rccm.201308-1483ST
Wells AU, Hirani N. Interstitial lung disease guideline. Thorax BMJ Publishing Group Ltd. 2008;63:v1-58.
Liu Y-M, Nepali K, Liou J-P. Idiopathic pulmonary fibrosis: current status, recent progress, and emerging targets. J Med Chem. 2017;60:527–53. DOI: 10.1021/acs.jmedchem.6b00935
Guiot J, Duysinx B, Seidel L, Henket M, Gester F, Bonhomme O, et al. Clinical experience in idiopathic pulmonary fibrosis: a retrospective study. Acta Clin Belg. 2018;73:139–43. DOI: 10.1080/17843286.2017.1399228
Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:242–8. DOI: 10.1164/ajrccm.155.1.9001319
Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010;12:213. DOI: 10.1186/ar3097
Shao T, Shi X, Yang S, Zhang W, Li X, Shu J, et al. Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations. Front Immunol. 2021;12:684699. DOI: 10.3389/fimmu.2021.684699
Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:10–7.
Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202:e36-69. DOI: 10.1164/rccm.202005-2032ST
Chen ES, Moller DR. Etiology of sarcoidosis. Clin Chest Med. 2008;29(365–77):vii.
Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150:967–72. DOI: 10.1164/ajrccm.150.4.7921471
Embil J, Warren P, Yakrus M, Stark R, Corne S, Forrest D, et al. Pulmonary illness associated with exposure to Mycobacterium-avium complex in hot tub water. Hypersensitivity pneumonitis or infection? Chest. 1997;111:813–6. DOI: 10.1378/chest.111.3.813
Hilberg O, Hoffmann-Vold A-M, Smith V, Bouros D, Kilpelainen M, Guiot J, et al. Epidemiology of ILDs and their progressive-fibrosing behaviour in six European countries. ERJ Open Research [Internet]. European Respiratory Society; 2021 [cited 2022 Jan 20]; Available from: https://openres.ersjournals.com/content/early/2021/11/11/23120541.00597-2021.
Papiris SA, Triantafillidou C, Manali ED, Kolilekas L, Baou K, Kagouridis K, et al. Combined pulmonary fibrosis and emphysema. Exp Rev Respir Med. 2013;7:19–31 (quiz 32). DOI: 10.1586/ers.12.80
Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest Am Coll Chest Phys. 2012;141:222–31.
Zantah M, Dotan Y, Dass C, Zhao H, Marchetti N, Criner GJ. Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema. Respir Res. 2020;21:164. DOI: 10.1186/s12931-020-01432-x
Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 2020;158:646. DOI: 10.1016/j.chest.2020.03.037
Kitaguchi Y, Fujimoto K, Hanaoka M, Honda T, Hotta J, Hirayama J. Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2014;9:805–11. DOI: 10.2147/COPD.S65621
Ryu JH, Colby TV, Hartman TE, Vassallo R. Smoking-related interstitial lung diseases: a concise review. Eur Respir J. 2001;17:122–32. DOI: 10.1183/09031936.01.17101220
Cigarette smoking and health. American Thoracic Society. Am J Respir Crit Care Med. 1996;153:861–5.
Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6:524–6. DOI: 10.1513/pats.200904-016DS
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. Am J Respir Crit Care Med Am Thorac Soc. 2017;195:557–82. DOI: 10.1164/rccm.201701-0218PP
Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76. DOI: 10.1164/ajrccm.163.5.2101039
Han MK, Agusti A, Celli BR, Criner GJ, Halpin DMG, Roche N, et al. From GOLD 0 to Pre-COPD. Am J Respir Crit Care Med Am Thorac Soc AJRCCM. 2021;203:414–23. DOI: 10.1164/rccm.202008-3328PP
Guiot J, Vaidyanathan A, Deprez L, Zerka F, Danthine D, Frix A-N, et al. A review in radiomics: making personalized medicine a reality via routine imaging. Med Res Rev. 2022;42:426–40. DOI: 10.1002/med.21846
Frix A-N, Cousin F, Refaee T, Bottari F, Vaidyanathan A, Desir C, et al. Radiomics in lung diseases imaging: state-of-the-art for clinicians. J Pers Med. 2021;11:602. DOI: 10.3390/jpm11070602
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. American thoracic society documents Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Japanese Respiratory Society. ATS; 2018.
Saku A, Fujisawa T, Nishimoto K, Yoshimura K, Hozumi H, Karayama M, et al. Prognostic significance of peripheral blood monocyte and neutrophil counts in rheumatoid arthritis-associated interstitial lung disease. Respir Med. 2021;182:106420. DOI: 10.1016/j.rmed.2021.106420
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med Lancet Publish Group. 2020;8:453–60. DOI: 10.1016/S2213-2600(20)30036-9
Guiot J, Cambier M, Boeckx A, Henket M, Nivelles O, Gester F, et al. Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p. Thorax. 2020;75:870–81. DOI: 10.1136/thoraxjnl-2019-214077
Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–5. DOI: 10.1136/thx.2006.062836
Wilcox AG. Small airway involvement in interstitial lung disease: radiologic evidence. Curr Opin Pulmon Med. 2000;6:399–403. DOI: 10.1097/00063198-200009000-00002
Dines DE, Stubbs SE, McDougall JC. Obstructive disease of the airways associated with stage I sarcoidosis. Mayo Clin Proc. 1978;53:788–91.
Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-associated lung disease. Eur Respir Rev Eur Respir Soc. 2015;24:1–16. DOI: 10.1183/09059180.00008014
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.